Bhattacharyya Parthasarathi, Dey Rana, Saha Dipanjan, Nag Saikat, Ghosh Subhasish, Chowdhury Sushmita Roy, Ganguly Dhiman
Department of Clinical pulmonary medicine, Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Lung India. 2015 Jan-Feb;32(1):40-3. doi: 10.4103/0970-2113.148447.
Lung lesions may develop from tissue reactions to known or unknown stimuli and present with different morphological descriptions. The pathogenesis may be induced and maintained by different bioactive substances, of which, the upregulation matrix metalloproteinases (MMPs) play a vital role. Inhibition of the MMPs, therefore, may be a prospective mode of therapy for such lesions.
A number of patients with lung lesions of different morphologies and presentations were treated empirically with long-term oral doxycycline (100 mg BID) upon exclusion of malignancy and infection in an open, single-arm, prospective, observational pilot study. The effect of the treatment was recorded on serial x-rays/computed tomography (CT) scans and the impact of treatment was measured with a visual analog scale (VAS) or a Likert-like scale. Furthermore, six independent pulmonologists' opinion (expressed on a '0' to '100' scale) were pooled with regard to the significance and the expectedness of such a change.
Twenty-six patients (mean age 49.33 years and male: female ratio = 10:3) with different types of pulmonary parenchymal/pleural lesions were treated with long-term oral doxycycline for a mean duration of 386.88 days related to the available radiological comparison. They showed a mean improvement of 3.99 on the Likert-like scale and 78% on the VAS scale. The mean significance of the change was 83.33%, with a mean expectedness of 18% as per the pooled opinion of the pulmonologists.
The significant and unexpected resolution of different tissue lesions from long-term doxycycline appears to be a novel observation. This needs proper scientific validation.
肺部病变可能由组织对已知或未知刺激的反应发展而来,并呈现出不同的形态学描述。其发病机制可能由不同的生物活性物质诱导并维持,其中基质金属蛋白酶(MMPs)的上调起着至关重要的作用。因此,抑制MMPs可能是治疗此类病变的一种潜在治疗方式。
在一项开放、单臂、前瞻性观察性试点研究中,排除恶性肿瘤和感染后,对多名具有不同形态和表现的肺部病变患者经验性地给予长期口服强力霉素(100毫克,每日两次)。在系列X线/计算机断层扫描(CT)上记录治疗效果,并使用视觉模拟量表(VAS)或类似李克特量表来衡量治疗的影响。此外,汇总了六位独立肺科医生(以“0”至“100”分制表示)关于这种变化的意义和预期性的意见。
26名患者(平均年龄49.33岁,男女比例为10:3)患有不同类型的肺实质/胸膜病变,接受了长期口服强力霉素治疗,与可用的放射学对照相关的平均治疗持续时间为386.88天。他们在类似李克特量表上的平均改善为3.99,在VAS量表上为78%。根据肺科医生的汇总意见,这种变化的平均意义为83.33%,平均预期性为18%。
长期使用强力霉素使不同组织病变得到显著且出乎意料的缓解似乎是一项新发现。这需要适当的科学验证。